How FDA Scrutiny and State Laws Could Reshape Medication Abortion
A year after President Donald Trump returned to office, federal rules governing the abortion pill mifepristone remain unchanged yet the political and regulatory environment around the drug is growing increasingly uncertain. The FDA’s ongoing safety review, renewed legal battles, and intensifying anti-abortion rhetoric from activists and administration officials have introduced new risks to a $6.9 … Read more